Top

AIDS Research and Therapy

Published in:

Open Access 01-12-2010 | Research

Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross - sectional study

Authors: Belay Tessema, Fantahun Biadglegne, Andargachew Mulu, Assefa Getachew, Frank Emmrich, Ulrich Sack

Published in: AIDS Research and Therapy | Issue 1/2010

Abstract

Background

Adequate antiretroviral drug potency is essential for obtaining therapeutic benefit, however, the behavioral aspects of proper adherence and readiness to medication, often determine therapeutic outcome. Therefore, this study aimed to assess the level and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy (HAART) among people living with HIV/AIDS (PLWHA) at Gondar University Teaching Hospital and Felege Hiwot Hospital in Northwest Ethiopia.

Methods

A cross-sectional study was conducted between July and September 2008 using structured interviewer-administered questionnaire. All consecutive adult outpatients who were receiving antiretroviral treatment for at least three months, seen at both hospitals during the study period and able to give informed consent were included in the study. Multivariate logistic regression was used to determine factors associated with nonadherence and nonreadiness.

Results

A total of 504 study subjects were included in this study. The prevalence rates of nonadherence and nonreadiness to HAART were 87 (17.3%) and 70 (13.9%) respectively. Multivariate logistic regression analysis revealed that medication adverse effects, nonreadiness to HAART, contact with psychiatric care service and having no goal had statistically significant association with nonadherence. Moreover, unwillingness to disclose HIV status was significantly associated with nonreadiness to HAART.

Conclusions

In this study the level of nonadherence and nonreadiness to HAART seems to be encouraging. Several factors associated with nonadherance and nonreadiness to HAART were identified. Efforts to minimize nonadherence and nonreadiness to HAART should be integrated in to regular clinical follow up of patients.

Sandstrom E, Uhnoo I, Ahlqvist-Rastad J, Bratt G, Berglund T, Gisslén M, Lindbäck S, Morfeldt L, Ståhle L, Sönnerborg A, Swedish Consensus Group: Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations. Scand J Infect Dis. 2003, 35: 155-167. 10.1080/00365540310006395CrossRefPubMed

UNAIDS/WHO: AIDS Epidemic Update December 2005. Geneva. 2005, 234-240.

UNAIDS and World Health Organization: AIDS epidemic update. 2003, 123-129.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ, Viral Activation Transfusion Study Investigators: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001, 135: 17-26.CrossRefPubMed

Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD, EuroSIDA study group: Decline in the AIDS and death rates in the Euro SIDA study: an observational study. Lancet. 2003, 362: 22-29. 10.1016/S0140-6736(03)13802-0CrossRefPubMed

Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998, 338: 853-860. 10.1056/NEJM199803263381301CrossRefPubMed

Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Bmj. 1997, 315: 1194-1199.PubMedCentralCrossRefPubMed

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999, 340: 1614-1622. 10.1056/NEJM199905273402102CrossRefPubMed

Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J, Pomerantz RJ: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Jama. 1999, 282: 1627-1632. 10.1001/jama.282.17.1627CrossRefPubMed

10.

Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999, 353: 863-868. 10.1016/S0140-6736(99)01122-8CrossRefPubMed

11.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the Euro SIDA study. Arch Intern Med. 2000, 160: 1123-1132. 10.1001/archinte.160.8.1123CrossRefPubMed

12.

Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995, 267: 483-489. 10.1126/science.7824947CrossRefPubMed

13.

Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996, 271: 1582-1586. 10.1126/science.271.5255.1582CrossRefPubMed

14.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003, 15: 1112-1118. 10.1086/378301.CrossRef

15.

Poppa A, Davidson O, Deutsch J, Godfrey D, Fisher M, Head S, Horne R, Sherr L, British HIV Association (BHIVA); British Association for Sexual Health and HIV (BASHH): Guidelines on provision of adherence support in individuals receiving ART. 2005, 2: 12-19.

16.

Ethiopian Ministry of Health: Ethiopian monthly antiretroviral treatment report. Addis Ababa (Ethiopia): Ministry of Health. 2008,

17.

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133: 21-30.CrossRefPubMed

18.

Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000, 14: 357-366. 10.1097/00002030-200003100-00008CrossRefPubMed

19.

Sodergard B: Adherance and readiness to antiretroviral treatment. Acta Universities Upsalinesis. PhD thesis. 2006,

20.

Gold RS, Hinchy J, Batrouney CG: The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV. Int J STD AIDS. 2000, 113: 61-70.

21.

Machtinger EL, Bangsberg DR: Adherence to HIV Antiretroviral therapy. HIV In sit. 2006, 7: 16-22. 10.1111/j.1468-1293.2005.00337.x.

22.

Tadios Y, Davey G: Retroviral drug adherence & its correlates in Addis Ababa, Ethiopia. Ethiop Med J. 2006, 44: 237-244.PubMed

23.

Mengesha A, Worku A: Assessment of antiretroviral treatment among HIV infected persons in the Ministry of Defense Hospitals. AAU; MPH Thesis. 2005,

24.

Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J: Socio demographic and psychological variables influencing adherence to antiretroviral therapy. PMED AIDS. 1999, 13: 1763-9. 10.1097/00002030-199909100-00021.CrossRef

25.

Gifford AL, Borman J E, Shively MJ, Wright BC, Richman DD, Bozzette SA: Predictors of self-reported adherence and plasma HIV concentrations in patients on multi drug antiretroviral regimens. JAIDS. 2000, 23: 386-95.PubMed

26.

Bonolo PDF, Casar CC, Acurio FA: Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. JAIDS. 2006, 19: 5-13.

27.

Laurent C, Fatou N, Gueye N: Long-term follow up of a cohort of patients on HAART in Senegal (abstract). 10th Conference on Retroviruses & Opportunistic Infections, Boston. 2003,

28.

Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, Melbourne K, Mitty J, Caro JJ: Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000, 22: 858-71. 10.1016/S0149-2918(00)80058-2CrossRefPubMed

29.

Singh N, Squier C, Sivek M, Wagener M, Nguyen H, Yu VL: Determinants of compliance with HAART therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS. 1996, 8: 261-269. 10.1080/09540129650125696.CrossRef

30.

Pratt R, Robinson N, Loveday HP, Pellowe CM, Franks PJ: Improvement in sexual drive and a falling viral load are associated with adherence to HAART therapy. 12th World AIDS Conference, Geneva Abstract 32343. 1998,

31.

Catz S, Heckman T, Kochman A: Adherence to HAART therapy among older adults living with HIV disease. 4th International Conference on the Biophysical Aspects of HIV Infection, Canada Ottawa. 1999, Poster 18,

32.

Buhrich N, Judd FK: HIV and psychiatric disorders. Managing HIV. Edited by: Stewart G. 1997, Sydney: Australasian Medical Publishing Company,

33.

Hayman J, Buhrich N: Psychiatric aspects. The AIDS Manual. Edited by: Gold J, Penny R, Ross M, Morey S, Stewart G, Donovan B, Berenger S. 1994, Sydney: Maclennon & Petty,

34.

Wright EJ, Brew BJ, Nurrie JN, McArthur JC: HIV-induced neurological disease. Managing HIV. Edited by: Stewart G. 1997, Sydney: Australasian Medical Publishing Company,

35.

Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, Inouye J, Henry SB, Nicholas PK, Portillo CJ: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs. 1999, 13: 185-197. 10.1089/apc.1999.13.185CrossRefPubMed

36.

Maisels L, Steinberg J, Tobias C: An investigation of why eligible patients do not receive HAART. AIDS Pat Care STDS. 2001, 15: 185-91. 10.1089/10872910151133701.CrossRef

37.

Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G: Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005, 17: 10-22. 10.1080/09540120412331305098CrossRefPubMed

38.

Wagner G, Miller LG: Is the influence of social desirability on patients' self-reported adherence overrated?. J Acquir Immune Defic Syndr. 2004, 35: 203-204. 10.1097/00126334-200402010-00016CrossRefPubMed

Title: Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross - sectional study
Authors: Belay Tessema
Fantahun Biadglegne
Andargachew Mulu
Assefa Getachew
Frank Emmrich
Ulrich Sack
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: AIDS Research and Therapy / Issue 1/2010
Electronic ISSN: 1742-6405
DOI: https://doi.org/10.1186/1742-6405-7-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross - sectional study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences

Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution

Specific eradication of HIV-1 from infected cultured cells

Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study

The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients

Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page